Sertaconazole
Sertaconazole is a benzothiophene-substituted imidazole antifungal agent used topically for the treatment of tinea pedis (athlete's foot) and atopic dermatitis complicated by fungal infection. It exerts dual antifungal activity by inhibiting fungal cytochrome P450-mediated lanosterol demethylation (disrupting ergosterol synthesis) and by direct membrane disruption through its benzothiophene moiety. The dual mechanism provides broad-spectrum activity against dermatophytes and Candida species.
Molecular Weight
437.8000 g/mol
LogP
6.30
TPSA
55.30 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
2D Structure
Cite this structure
Embed this structure
SMILES
Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1
InChI
InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2
Molecular Formula
C20H15Cl3N2OS
HBD / HBA
- / 3
Rotatable Bonds
6
Heavy Atoms
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Sertaconazole is a benzothiophene-substituted imidazole antifungal agent used topically for the treatment of tinea pedis (athlete's foot) and atopic dermatitis complicated by fungal infection. It exerts dual antifungal activity by inhibiting fungal cytochrome P450-mediated lanosterol demethylation (disrupting ergosterol synthesis) and by direct membrane disruption through its benzothiophene moiety. The dual mechanism provides broad-spectrum activity against dermatophytes and Candida species.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Sertaconazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201196. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 65863. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sertaconazole"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sertaconazole/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sertaconazole/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sertaconazole/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sertaconazole"></drugfyi-drug>